Gastrointestinal Cancer News

The addition of ramucirumab to first-line chemotherapy conferred a 25% reduction in risk for disease progression or death among treatment-naive patients with metastatic gastric or gastroesophageal junction adenocarcinoma, according to results of a randomized phase 3 study scheduled for presentation at the Gastrointestinal Cancers Symposium.

Older people living with HIV remain at an elevated risk for cancer, according to findings published in Clinical Infectious Diseases.

Combining nivolumab with ipilimumab demonstrated clinical benefit and a manageable safety profile among patients with DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer, according to results of a study scheduled for presentation at the Gastrointestinal Cancers Symposium.

Patients with stage III and high-risk stage II colorectal cancer had worse DFS if they had right-sided tumors compared with left-sided tumors, according to results of a study scheduled for presentation at the Gastrointestinal Cancers Symposium.

A test that identifies circulating tumor cells present in the bloodstream accurately detected early-stage colorectal cancer, according to results of a study scheduled for presentation at the Gastrointestinal Cancers Symposium.

Latino patients with colorectal cancer had a 13% prevalence rate of mismatch repair-deficient tumors, a rate that appeared consistent with those of non-Hispanic white patients, according to study findings.

Long-term night shift work increased women’s risk for cancer by 19%, according to a study published in Cancer Epidemiology, Biomarkers & Prevention.

The American Institute for Cancer Research awarded $1.1 million worth of grants to fund seven research projects designed to better understand how physical activity, diet and weight management affect cancer prevention and survivorship.

The cancer mortality rate dropped 1.7% from 2014 to 2015, continuing a decades-long decline reaching 26% since 1991, according to Cancer Statistics 2018, the American Cancer Society’s comprehensive annual report on cancer incidence, mortality and survival.

Researchers observed a low rate of complete response to sorafenib treatment for hepatocellular carcinoma in a recent retrospective study; however, nearly all patients who achieved complete response also developed dermatologic adverse events, which may provide a correlation between toxicity and treatment response.